
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is in a strong financial position with a high cash balance and low debt, allowing for potential investments in future growth opportunities. Although recent production results were below expectations, the company's long-term outlook remains positive with a strong pipeline of products and solutions in the life science technology industry. Additionally, their acquisition of Prime Mining in 2025 has added further growth potential to their portfolio.
Bears say
10x Genomics is currently experiencing business growth and has released a positive Los Reyes PEA, but Q2 production results show that this growth may be skewed towards the second half of 2026. While the PEA delivered a strong after-tax NPV and IRR, the upfront capex of US$515M and LOM production and AISC figures may be concerning and could impact the company's financials in the long term.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares